Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
MUMBAI, India and WARREN, N.J., Sept. 3, 2026 /PRNewswire/ -- Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087) (NSE: CIPLA) today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as...
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


